{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:06:46Z","timestamp":1785294406522,"version":"3.55.0"},"reference-count":18,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thromboprophylaxis with low molecular weight heparin in hospitalized patients with COVID-19 is mandatory, unless contraindicated. Given the links between inflammation and thrombosis, the use of higher doses of anticoagulants could improve outcomes. We conducted an open-label, multicenter, randomized, controlled trial in adult patients hospitalized with nonsevere COVID-19 pneumonia and elevated D-dimer. Patients were randomized to therapeutic-dose bemiparin (115\u2009IU\/kg daily) versus standard prophylaxis (bemiparin 3,500\u2009IU daily), for 10 days. The primary efficacy outcome was a composite of death, intensive care unit admission, need of mechanical ventilation support, development of moderate\/severe acute respiratory distress, and venous or arterial thrombosis within 10 days of enrollment. The primary safety outcome was major bleeding (International Society on Thrombosis and Haemostasis criteria). A prespecified interim analysis was performed when 40% of the planned study population was reached. From October 2020 to May 2021, 70 patients were randomized at 5 sites and 65 were included in the primary analysis; 32 patients allocated to therapeutic dose and 33 to standard prophylactic dose. The primary efficacy outcome occurred in 7 patients (22%) in the therapeutic-dose group and 6 patients (18%) in the prophylactic-dose (absolute risk difference 3.6% [95% confidence interval [CI], \u201316% \u201324%]; odds ratio 1.26 [95% CI, 0.37\u20134.26]; p\u2009=\u20090.95). Discharge in the first 10 days was possible in 66 and 79% of patients, respectively. No major bleeding event was registered. Therefore, in patients with COVID-19 hospitalized with nonsevere pneumonia but elevated D-dimer, the use of a short course of therapeutic-dose bemiparin does not appear to improve clinical outcomes compared with standard prophylactic doses. Trial Registration: ClinicalTrials.gov NCT04604327.<\/jats:p>","DOI":"10.1055\/a-1667-7534","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T03:58:48Z","timestamp":1634097528000},"page":"295-299","source":"Crossref","is-referenced-by-count":48,"title":["Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial"],"prefix":"10.1055","volume":"122","clinical-trial-number":[{"clinical-trial-number":"nct04604327","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mar\u00eda","family":"Marcos-Jubilar","sequence":"additional","affiliation":[{"name":"Hematology Service, Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carmona-Torre","sequence":"additional","affiliation":[{"name":"Divison of Infectious Diseases, Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Vidal","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez-D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-9883","authenticated-orcid":false,"given":"Pedro","family":"Ruiz-Artacho","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Cl\u00ednica Universidad de Navarra, Madrid, Spain"},{"name":"CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Filella","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carbonell","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario de Salamanca-IBSAL, Universidad de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Llamas","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez-D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Alegre","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"S\u00e1daba","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"N\u00fa\u00f1ez-C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Yuste","sequence":"additional","affiliation":[{"name":"Divison of Infectious Diseases, Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Lecumberri","sequence":"additional","affiliation":[{"name":"Hematology Service, Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"},{"name":"CIBER Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BEMICOP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report","volume":"158","author":"L K Moores","year":"2020","journal-title":"Chest"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"A Cuker","year":"2021","journal-title":"Blood Adv"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","article-title":"Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"159","author":"D Jim\u00e9nez","year":"2021","journal-title":"Chest"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/ATVBAHA.120.314514","article-title":"Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses","volume":"40","author":"N Mackman","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref6","first-page":"167","article-title":"COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)","volume":"18","author":"M Marietta","year":"2020","journal-title":"Blood Transfus"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.14929","article-title":"Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"A C Spyropoulos","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0040-1721664","article-title":"Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis","volume":"121","author":"R Patell","year":"2021","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"C J Mycroft-West","year":"2020","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","article-title":"Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review","volume":"77","author":"A H Talasaz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1111\/jth.15094","article-title":"Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration","volume":"18","author":"T Tritschler","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref14","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial","volume":"325","author":"P Sadeghipour","year":"2021","journal-title":"JAMA"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with COVID-19","volume":"385","author":"E C Goligher","year":"2021","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"R D Lopes","year":"2021","journal-title":"Lancet"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19","volume":"385","author":"P R Lawler","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMc2102446","article-title":"Platform trials - beware the noncomparable control group","volume":"384","author":"L E Dodd","year":"2021","journal-title":"N Engl J Med"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/jth.15400","article-title":"Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis","volume":"19","author":"P Demelo-Rodriguez","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1667-7534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:48:15Z","timestamp":1660142895000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1667-7534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":18,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,2,7]]},"published-print":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1667-7534","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,12]]},"published":{"date-parts":[[2021,10,12]]}}}